Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/57642
Tipo
ArtículoDerechos de autor
Acceso restringido
Colecciones
Metadatos
Mostrar el registro completo del ítem
BENZNIDAZOLE: HERO OR VILLAIN OF CELLULAR IMMUNE RESPONSE IN CHRONIC CHAGAS DISEASE PATIENTS?
Innate immunity
Immune response
Benznidazole
Surface receptors
Trypanosoma cruzi
Etiological treatment
Autor
Resumen en ingles
Although the treatment of chronic Chagas disease (CCD) patients with Benznidazole (Bz) is still controversial, its
use may prevent or delay the progression of the disease to the most severe forms. One of the main factors that can
influence the effectiveness of the treatment is the possible cooperation between drug effect and the host immune
response. Herein, we evaluated the immune response of peripheral blood mononuclear cells (PBMCs) infected
with Trypanosoma cruzi and submitted to Bz treatment. Blood samples of CCD patients (n = 7) and non-infected
individuals (n = 6) were drawn to obtain PBMCs. After cell culture, the supernatants were harvested and stored,
and the cell analyzed by flow cytometer. The results showed that Bz positively regulated the molecular process of
cell activation (CD80) and antigen presentation (HLA-DR), increased phagocytosis receptor and macrophage
activation (CD64), and did not induce an exacerbated immune response. In conclusion, these results highlight the
relevance of using Bz that, despite not being a true hero, it is also not a villain, as it presents a wide range of
pharmacological/immunological response interactions, important for the immune balance in the clinical pro-
gression of CCD.
Palabras clave en ingles
Chagas diseaseInnate immunity
Immune response
Benznidazole
Surface receptors
Trypanosoma cruzi
Etiological treatment
Compartir